Skip to main navigation Skip to search Skip to main content

A multicenter, Randomized, controlled phase 2 study: Efficacy and safety of I-131-1095 Radiotherapy in combination with enzalutamide in metastatic castration-resistant prOstate cancer (mCRPC) patients Who are F-DCFPyL prostate-specific. . .

Upstate Medical University

Project: Research

Project Details

StatusFinished
Effective start/end date05/4/20 → 11/3/25

Funding

  • Progenics Pharmaceuticals Incorporated: $367,246.95